Indication: Urothelial Cancer

A Phase II Open Label, Study of IMMU-132 in Metastatic Urothelial Cancer after Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1 Based Immunotherapy

Metastatic

Sub-indication: Metastatic Urothelial Cancer After Failure of Platinum-Based Regimen or Anti-PD-1/ PD-L1

Line of Therapy: 2nd line

Drug Study

Principal Investigator: Arash Rezazadeh, M.D.
Norton Cancer Institute

Sponsor: Immunomedics, Inc

Learn more at ClinicalTrials.gov

Email for more information: GU-NCIResearch@nortonhealthcare.org

Search our entire site.

Schedule an Appointment

Select an appointment date and time from available spots listed below.